Biotech Reports Eye-Catching Topline Results from RSV Vaccine Study

Biotech Reports Eye-Catching Topline Results from RSV Vaccine Study - Streetwise Reports

June 25, 2019

Biotech Reports Eye-Catching Topline Results from RSV Vaccine Study Streetwise Reports

In a June 14 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that Enanta Pharmaceuticals Inc.'s (ENTA:NASDAQ) EDP-928 vaccine ...

RSV Treatment

Biotech Reports Eye-Catching Topline Results from RSV Vaccine Study - Streetwise Reports

Comments

Post a Comment

Popular posts from this blog

Analysis | The Keys to Speed in Race for Vaccine, and Its Perils - Washington Post

Local family warns parents about RSV, as number of infant cases increases - KLRT - FOX16.com

Prematurity Awareness Month: Educating the public about Respiratory Syncytial Virus is vital, claims leading consultant - ZAWYA